2023 Program
12 October 2023
ANCA Associated Vasculitis
By the end of this symposium, participants will be able to describe recent discoveries in clinical and translational research and innovations in care for patients with vasculitis, which aims to improve the long term outcomes
Welcome and Opening Remarks
7:50 am
Presented by the Symposium Planning Committee
Complement and ANCA Associated Vasculitis
8:00 am
Presented by Dr. Christoph Licht
Objective: By the end of this session participants will be able to review the role of complement in the pathogenesis of ANCA vasculitis to guide possible treatment strategies
Biomarkers of Vasculitides
9:00 am
Presented by Dr. May Choi
Objective: By the end of this session participants will be able to recognize the utility of biomarkers in the diagnosis, treatment and prognosis in vasculitides
New Treatments in ANCA Associated Vasculitis
9:45am
Presented by Dr. Michael Walsh
Objective: By the end of this session participants will be able to review of new treatment for ANCA disease as adjunctive or replacement to current therapies
Break
10:30 am
Interesting Case Review
10:45 am
Case 1 presented by Dr. Jessica Nguyen
Case 2 presented by Dr. Mats Junek
Case 3 presented by Dr. Punit Chhajed
Case 4 presented by Dr. Kelly Garrity
Objective: By the end of this session participants will be able to restate the treatment of rare/interesting vasculitis cases
Lunch
12:05 pm
Chimeric Antigen Receptor (CAR)-T cells; is there a role in Vasculitis?
1:00 pm
Presented by Dr. Tony Truong
Objective: By the end of this session participants will be able to describe the possibilities of specific B-Cell depletion with CAR-T cells to treat vasculitis
Bronchial and tracheal involvement in ANCA Associated Vasculitis
1:45 pm
Presented by Dr. James Brookes
Objective: By the end of this session participants will be able to recognise the spectrum of airway disease and treatment in ANCA Associated Vasculitis
Break
2:30 pm
Big Debate: High or Low Dose Prednisone in ANCA Associated Vasculitis
3:00 pm
Presented by Dr. Marinka Twilt & Dr. Michael Walsh
Objective: By the end of this session participants will be able to express the perspectives of too much or too little prednisone in the management of ANCA Associated Vasculitis
Closing Remarks
4:00 pm
Presented by the Symposium Planning Committee